Rumiko Shimazawa, Masayuki Ikeda. Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech). Journal of Pharmaceutical Policy and Practice. 2021. 14. 1. 46-46
Rumiko Shimazawa, Masayuki Ikeda. Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparison. British Journal of Clinical Pharmacology. 2021. 87. 10. 3938-3948
Rumiko Shimazawa, Masayuki Ikeda. Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan. Expert review of molecular diagnostics. 2020. 20. 6. 601-610